Open Access[Corrigendum] Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor�MK2206 in mammary cancer models
Author(s) -
Ronald A. Lubet,
Ver E. Steele,
M. Juliana,
Ann M. Bode,
Fariba Moeinpour,
Clinton J. Grubbs
Publication year - 2018
Publication title -
oncology reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.094
H-Index - 96
eISSN - 1791-2431
pISSN - 1021-335X
DOI - 10.3892/or.2018.6802
Subject(s) - lapatinib , gefitinib , cancer , oncogene , egfr inhibitors , medicine , cancer research , dosing , pharmacology , oncology , breast cancer , cell cycle , trastuzumab , epidermal growth factor receptor
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom